Nuvation Bio Inc. Payments to Acquire Marketable Securities
Nuvation Bio Inc. (NUVB) reported Payments to Acquire Marketable Securities of $149.84 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-06
- Nuvation Bio Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $67.69M, a 17.11% decline year-over-year.
- Nuvation Bio Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $82.15M, a 35.32% increase year-over-year.
- Nuvation Bio Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $44.90M, a 40.13% increase year-over-year.
- Nuvation Bio Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $167.14M, a 95.11% increase year-over-year.
- Nuvation Bio Inc. payments to acquire marketable securities for fiscal 2025 was $354.42M, a 4.35% increase from fiscal 2024.
- Nuvation Bio Inc. payments to acquire marketable securities for fiscal 2024 was $339.64M, a 51.71% decline from fiscal 2023.
- Nuvation Bio Inc. payments to acquire marketable securities for fiscal 2023 was $703.37M, a 35.18% increase from fiscal 2022.
- Nuvation Bio Inc. payments to acquire marketable securities for fiscal 2022 was $520.31M, a 14.61% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $67.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $149.84M 10-Q · filed 2026-08-06 | $194.74M derived: sum of 3 quarters · filed 2026-08-06 | $361.88M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $82.15M 10-Q · filed 2026-05-04 | $127.05M derived: sum of 2 quarters · filed 2026-05-04 | $294.18M derived: sum of 3 quarters · filed 2026-05-04 | $375.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $44.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $212.04M derived: sum of 2 quarters · filed 2026-03-02 | $293.71M derived: sum of 3 quarters · filed 2026-08-06 | $354.42M 10-K · filed 2026-03-02 |
| 2025-09-30 | $167.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $248.81M derived: sum of 2 quarters · filed 2026-08-06 | $309.51M 10-Q · filed 2025-11-03 | $341.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $81.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $142.38M 10-Q · filed 2026-08-06 | $174.42M derived: sum of 3 quarters · filed 2026-08-06 | $260.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $60.71M 10-Q · filed 2026-05-04 | $92.75M derived: sum of 2 quarters · filed 2026-05-04 | $178.41M derived: sum of 3 quarters · filed 2026-05-04 | $271.94M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $32.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $117.71M derived: sum of 2 quarters · filed 2026-03-02 | $211.24M derived: sum of 3 quarters · filed 2026-03-02 | $339.64M 10-K · filed 2026-03-02 |
| 2024-09-30 | $85.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $179.19M derived: sum of 2 quarters · filed 2025-11-03 | $307.60M 10-Q · filed 2025-11-03 | $456.34M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $93.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $221.94M 10-Q · filed 2025-08-07 | $370.68M derived: sum of 3 quarters · filed 2025-08-07 | $481.51M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $128.41M 10-Q · filed 2025-05-07 | $277.15M derived: sum of 2 quarters · filed 2025-05-07 | $387.98M derived: sum of 3 quarters · filed 2025-05-07 | $594.82M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $148.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $259.57M derived: sum of 2 quarters · filed 2025-03-06 | $466.41M derived: sum of 3 quarters · filed 2025-03-06 | $703.37M 10-K · filed 2025-03-06 |
| 2023-09-30 | $110.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $317.67M derived: sum of 2 quarters · filed 2024-11-06 | $554.63M 10-Q · filed 2024-11-06 | $692.34M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $206.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $443.80M 10-Q · filed 2024-08-05 | $581.51M derived: sum of 3 quarters · filed 2024-08-05 | $701.43M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $236.97M 10-Q · filed 2024-05-14 | $374.68M derived: sum of 2 quarters · filed 2024-05-14 | $494.60M derived: sum of 3 quarters · filed 2024-05-14 | $625.61M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $137.71M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $257.63M derived: sum of 2 quarters · filed 2024-02-29 | $388.64M derived: sum of 3 quarters · filed 2024-02-29 | $520.31M 10-K · filed 2024-02-29 |
| 2022-09-30 | $119.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $250.93M derived: sum of 2 quarters · filed 2023-11-02 | $382.60M 10-Q · filed 2023-11-02 | $637.05M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $131.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $262.67M 10-Q · filed 2023-08-03 | $517.12M derived: sum of 3 quarters · filed 2023-08-03 | $640.30M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $131.67M 10-Q · filed 2023-05-04 | $386.12M derived: sum of 2 quarters · filed 2023-05-04 | $509.30M derived: sum of 3 quarters · filed 2023-05-04 | $716.46M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $254.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $377.63M derived: sum of 2 quarters · filed 2023-03-15 | $584.79M derived: sum of 3 quarters · filed 2023-03-15 | $609.30M 10-K · filed 2023-03-15 |
| 2021-09-30 | $123.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $330.33M derived: sum of 2 quarters · filed 2022-11-03 | $354.85M 10-Q · filed 2022-11-03 | $490.90M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $207.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $231.67M 10-Q · filed 2022-08-04 | $367.73M derived: sum of 3 quarters · filed 2022-08-04 | $368.82M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $24.51M 10-Q · filed 2022-05-09 | $160.57M derived: sum of 2 quarters · filed 2022-05-09 | $161.66M derived: sum of 3 quarters · filed 2022-05-09 | $166.26M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $136.06M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $137.15M derived: sum of 2 quarters · filed 2022-02-28 | $141.75M derived: sum of 3 quarters · filed 2022-02-28 | $143.29M 10-K · filed 2022-02-28 |
| 2020-09-30 | $1.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $5.69M derived: sum of 2 quarters · filed 2021-11-10 | $7.23M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $4.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $6.14M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $1.54M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |